NCT02132130: A reported trial by Novartis Pharmaceuticals
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT02132130 |
|---|---|
| Title | A Three-part, Multicenter, Open Label, Single Dose Study to Assess the Safety, Tolerability, and Efficacy of Intra Labyrinthine (IL) CGF166 in Patients With Severe-to-profound Hearing Loss |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls a "probable Applicable Clinical Trial" |
| Start date | June 23, 2014 |
| Completion date | Dec. 9, 2019 |
| Required reporting date | Dec. 8, 2020, midnight |
| Actual reporting date | Dec. 2, 2020 |
| Date last checked at ClinicalTrials.gov | Dec. 5, 2025 |
| Days late | None |